Accolade, Inc. (NASDAQ:ACCD) President Robert N. Cavanaugh recently sold 475 shares of the company's common stock, according to a regulatory filing. The shares were sold on November 4 at a price of $3.149 each, totaling approximately $1,495. This transaction was part of a mandatory sell-to-cover arrangement to fulfill tax withholding obligations related to the vesting of restricted stock units (RSUs).
Earlier, on November 1, Cavanaugh acquired 1,569 shares of Accolade's common stock through the conversion of RSUs. This acquisition did not involve any cash transaction as each RSU converted into one share of common stock. Following these transactions, Cavanaugh holds 198,649 shares directly.
In other recent news, Accolade Inc (NASDAQ:ACCD). has been the subject of several financial outlook adjustments from analyst firms. Wells Fargo (NYSE:WFC) revised Accolade's price target downwards to $6.00, citing concerns over the timing of deal closures that may impact the company's anticipated growth. Despite this, the firm maintained an Equal Weight rating on the stock, suggesting a balanced risk and reward profile.
Accolade also reported strong second-quarter results for 2025, exceeding revenue expectations with a total of $106.4 million and surpassing its adjusted EBITDA guidance. The company confirmed its fiscal year 2025 revenue guidance between $460 million to $475 million and projected a positive adjusted EBITDA of $15 million to $20 million.
Several other firms, including Stephens, Canaccord Genuity, Truist Securities, and BofA Securities, have revised their price targets for Accolade while maintaining Buy ratings. Notably, Stephens and Canaccord Genuity adjusted their models to reflect a 12% revenue growth for Accolade in fiscal years 2025 and 2026.
Accolade's management has expressed optimism about a strong pipeline with diversification across employers, health plans, and government segments. However, slower revenue growth is anticipated in fiscal year 2026 due to staggered launches. These are some of the recent developments in Accolade's financial landscape.
InvestingPro Insights
As Accolade's President Robert N. Cavanaugh adjusts his holdings, investors may find additional context in the company's current financial landscape. According to InvestingPro data, Accolade's market capitalization stands at $259.33 million, reflecting its position in the healthcare technology sector. The company's revenue for the last twelve months as of Q2 2023 was $441.03 million, with a revenue growth of 16.04% over the same period.
Despite this growth, InvestingPro Tips highlight that Accolade is not currently profitable, with analysts not anticipating profitability in the near term. This aligns with the company's operating income margin of -21.24% for the last twelve months. The stock's recent performance has been challenging, with InvestingPro data showing a 6-month price total return of -58.22% as of the latest available data.
It's worth noting that Accolade's stock price movements have been quite volatile, and the company is trading near its 52-week low. This volatility may be of interest to investors considering the recent insider transaction. On a positive note, InvestingPro Tips indicate that Accolade's liquid assets exceed its short-term obligations, suggesting a degree of financial stability despite the current challenges.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for Accolade, providing a deeper dive into the company's financial health and market position. These insights could be particularly valuable given the recent insider activity and the company's current market dynamics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.